Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01212276 · ClinicalTrials.gov registry record · Phase 1
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
A Phase 1 study, sponsored by Morphotek.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01212276: Clinical Trial Phase 1 study, sponsored by Morphotek.
NCT01212276 is a Phase 1 study that was terminated before completion, run by Morphotek. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01212276, a Phase 1 study, was terminated before completion, sponsored by Morphotek.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
Interventions
- DRUG MORAb-028
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Why NCT01212276 stopped before completion
NCT01212276 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which MORAb-028 is the first listed.
NCT01212276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01212276 about?
NCT01212276 is a clinical study titled "A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma". The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
What is the current status of trial NCT01212276?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-12. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01212276?
The interventions under investigation include: MORAb-028 (DRUG).
Who is sponsoring clinical trial NCT01212276?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01212276's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia